Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 22

1.

Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding.

Graham RA, Lum BL, Cheeti S, Jin JY, Jorga K, Von Hoff DD, Rudin CM, Reddy JC, Low JA, Lorusso PM.

Clin Cancer Res. 2011 Apr 15;17(8):2512-20. doi: 10.1158/1078-0432.CCR-10-2736. Epub 2011 Feb 7.

PMID:
21300760
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.

Cirrone F, Harris CS.

Clin Ther. 2012 Oct;34(10):2039-50. doi: 10.1016/j.clinthera.2012.08.011. Epub 2012 Oct 1. Review.

PMID:
23036338
[PubMed - indexed for MEDLINE]
3.

Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.

Proctor AE, Thompson LA, O'Bryant CL.

Ann Pharmacother. 2014 Jan;48(1):99-106. doi: 10.1177/1060028013506696. Epub 2013 Oct 15. Review.

PMID:
24259609
[PubMed - indexed for MEDLINE]
4.

Vismodegib.

Meiss F, Zeiser R.

Recent Results Cancer Res. 2014;201:405-17. doi: 10.1007/978-3-642-54490-3_25. Review.

PMID:
24756807
[PubMed - indexed for MEDLINE]
5.

Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers.

De Smaele E, Ferretti E, Gulino A.

Curr Opin Investig Drugs. 2010 Jun;11(6):707-18. Review.

PMID:
20496266
[PubMed - indexed for MEDLINE]
6.

Vismodegib: in locally advanced or metastatic basal cell carcinoma.

Keating GM.

Drugs. 2012 Jul 30;72(11):1535-41. doi: 10.2165/11209590-000000000-00000. Review.

PMID:
22788238
[PubMed - indexed for MEDLINE]
7.

Vismodegib: a hedgehog pathway inhibitor for locally advanced and metastatic basal cell carcinomas.

Sobanko JF, Okman J, Miller C.

J Drugs Dermatol. 2013 Oct;12(10 Suppl):s154-5. Review.

PMID:
24085062
[PubMed - indexed for MEDLINE]
8.

Protein binding in antiretroviral therapies.

Boffito M, Back DJ, Blaschke TF, Rowland M, Bertz RJ, Gerber JG, Miller V.

AIDS Res Hum Retroviruses. 2003 Sep;19(9):825-35. Review.

PMID:
14585213
[PubMed - indexed for MEDLINE]
9.

Mechanisms of Hedgehog pathway activation in cancer and implications for therapy.

Scales SJ, de Sauvage FJ.

Trends Pharmacol Sci. 2009 Jun;30(6):303-12. doi: 10.1016/j.tips.2009.03.007. Epub 2009 May 13. Review.

PMID:
19443052
[PubMed - indexed for MEDLINE]
10.

Vismodegib in basal cell carcinoma.

Amaria RN, Bowles DW, Lewis KD, Jimeno A.

Drugs Today (Barc). 2012 Jul;48(7):459-67. doi: 10.1358/dot.2012.48.7.1808490. Review.

PMID:
22844657
[PubMed - indexed for MEDLINE]
11.

GDC-0449--targeting the hedgehog signaling pathway.

Dierks C.

Recent Results Cancer Res. 2010;184:235-8. doi: 10.1007/978-3-642-01222-8_17. Review.

PMID:
20072843
[PubMed - indexed for MEDLINE]
12.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
[PubMed - indexed for MEDLINE]
13.

Vismodegib: the first drug approved for advanced and metastatic basal cell carcinoma.

Dubey AK, Dubey S, Handu SS, Qazi MA.

J Postgrad Med. 2013 Jan-Mar;59(1):48-50. Review.

PMID:
23525058
[PubMed - indexed for MEDLINE]
Free Article
14.

Effect of alpha-1-acid glycoprotein binding on pharmacokinetics and pharmacodynamics.

Huang Z, Ung T.

Curr Drug Metab. 2013 Feb;14(2):226-38. Review.

PMID:
23092311
[PubMed - indexed for MEDLINE]
15.

[Hedgehog inhibitors. New promising treatment of advanced basal cell carcinoma].

Wolodarski M, Lapins J, Hansson J.

Lakartidningen. 2013 Apr 24-May 6;110(17-18):886-8. Review. Swedish. No abstract available.

PMID:
23717940
[PubMed - indexed for MEDLINE]
16.

Emerging treatments and signaling pathway inhibitors.

Tang JY, Marghoob AA.

Semin Cutan Med Surg. 2011 Dec;30(4 Suppl):S14-8. doi: 10.1016/j.sder.2011.11.002. Review.

PMID:
22177102
[PubMed - indexed for MEDLINE]
17.

Vismodegib for the treatment of basal cell skin cancer.

Poggi L, Kolesar JM.

Am J Health Syst Pharm. 2013 Jun 15;70(12):1033-8. doi: 10.2146/ajhp120311. Review.

PMID:
23719880
[PubMed - indexed for MEDLINE]
18.

Treatment of margin positive basal cell carcinoma with vismodegib: case report and consideration of treatment options and their implications.

Bayers S, Kapp DL, Beer KR, Slavin B.

J Drugs Dermatol. 2013 Oct;12(10 Suppl):s147-50. Review.

PMID:
24085060
[PubMed - indexed for MEDLINE]
19.

Basal cell carcinoma: hedgehog pathway inhibitors and beyond.

Walls B.

Cutis. 2013 Jun;91(6):E1-4. Review. No abstract available.

PMID:
23837158
[PubMed - indexed for MEDLINE]
20.

The impact of inoperable advanced basal cell carcinoma: the economic, physical, and psychological burden of the disease.

Haves AW, Schaffer PR, Carucci JA.

J Drugs Dermatol. 2013 Oct;12(10 Suppl):s151-3. Review.

PMID:
24085061
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk